$831 Million is the total value of Ikarian Capital, LLC's 140 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $64,122,000 | – | 1,500 | +100.0% | 7.71% | – |
| QQQ | New | INVESCO QQQ TRput | $42,992,400 | – | 1,200 | +100.0% | 5.17% | – |
| XBI | New | SPDR SER TRput | $36,510,000 | – | 5,000 | +100.0% | 4.39% | – |
| MRNA | New | MODERNA INCput | $25,233,747 | – | 2,443 | +100.0% | 3.04% | – |
| ABBV | New | ABBVIE INCcall | $19,750,450 | – | 1,325 | +100.0% | 2.38% | – |
| New | SOLENO THERAPEUTICS INC | $15,838,608 | – | 536,720 | +100.0% | 1.90% | – | |
| AKRO | New | AKERO THERAPEUTICS INCput | $15,421,842 | – | 3,049 | +100.0% | 1.86% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS INput | $13,510,882 | – | 4,543 | +100.0% | 1.62% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $13,415,335 | – | 654,726 | +100.0% | 1.61% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS INcall | $12,056,596 | – | 4,054 | +100.0% | 1.45% | – |
| IMVT | New | IMMUNOVANT INC | $11,432,311 | – | 297,794 | +100.0% | 1.38% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INCput | $10,890,000 | – | 7,500 | +100.0% | 1.31% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $10,116,001 | – | 200,000 | +100.0% | 1.22% | – |
| AKRO | New | AKERO THERAPEUTICS INCcall | $10,060,362 | – | 1,989 | +100.0% | 1.21% | – |
| TARS | New | TARSUS PHARMACEUTICALS INC | $9,214,083 | – | 518,519 | +100.0% | 1.11% | – |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $8,996,460 | – | 2,365 | +100.0% | 1.08% | – |
| New | DISC MEDICINE INCput | $7,169,148 | – | 1,526 | +100.0% | 0.86% | – | |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $6,949,086 | – | 137,824 | +100.0% | 0.84% | – | |
| CYTK | New | CYTOKINETICS INCcall | $5,995,110 | – | 2,035 | +100.0% | 0.72% | – |
| CYTK | New | CYTOKINETICS INCput | $5,995,110 | – | 2,035 | +100.0% | 0.72% | – |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $5,913,527 | – | 505,862 | +100.0% | 0.71% | – |
| AMAM | New | AMBRX BIOPHARMA INCcall | $5,671,800 | – | 4,932 | +100.0% | 0.68% | – |
| RVMD | New | REVOLUTION MEDICINES INCput | $5,632,880 | – | 2,035 | +100.0% | 0.68% | – |
| ETNB | New | 89BIO INCcall | $5,410,176 | – | 3,504 | +100.0% | 0.65% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS PLCcall | $5,410,592 | – | 418 | +100.0% | 0.65% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $4,123,684 | – | 178,360 | +100.0% | 0.50% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $3,847,501 | – | 2,250,000 | +100.0% | 0.46% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $3,793,857 | – | 346,471 | +100.0% | 0.46% | – |
| New | AMYLYX PHARMACEUTICALS INCcall | $3,781,015 | – | 2,065 | +100.0% | 0.46% | – | |
| SNDX | New | SYNDAX PHARMACEUTICALS INCcall | $3,630,000 | – | 2,500 | +100.0% | 0.44% | – |
| EYPT | New | EYEPOINT PHARMACEUTICALS INCput | $3,585,113 | – | 4,487 | +100.0% | 0.43% | – |
| ITOS | New | ITEOS THERAPEUTICS INCcall | $3,346,320 | – | 3,056 | +100.0% | 0.40% | – |
| CBAY | New | CYMABAY THERAPEUTICS INCcall | $3,324,930 | – | 2,230 | +100.0% | 0.40% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $3,238,043 | – | 865,787 | +100.0% | 0.39% | – |
| VERV | New | VERVE THERAPEUTICS INCput | $3,199,638 | – | 2,413 | +100.0% | 0.38% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INCcall | $3,073,500 | – | 1,500 | +100.0% | 0.37% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $2,697,329 | – | 682,868 | +100.0% | 0.32% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWput | $2,672,192 | – | 971 | +100.0% | 0.32% | – |
| VERV | New | VERVE THERAPEUTICS INCcall | $2,652,000 | – | 2,000 | +100.0% | 0.32% | – |
| ACRS | New | ACLARIS THERAPEUTICS INCcall | $2,491,345 | – | 3,637 | +100.0% | 0.30% | – |
| RVPH | New | REVIVA PHARMACEUTCLS HLDGS Icall | $2,486,360 | – | 5,095 | +100.0% | 0.30% | – |
| DYN | New | DYNE THERAPEUTICS INCcall | $2,442,496 | – | 2,726 | +100.0% | 0.29% | – |
| New | NUVALENT INCput | $2,404,231 | – | 523 | +100.0% | 0.29% | – | |
| IFRX | New | INFLARX NV | $2,052,040 | – | 688,604 | +100.0% | 0.25% | – |
| NUVB | New | NUVATION BIO INC | $1,638,623 | – | 1,222,852 | +100.0% | 0.20% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,555,112 | – | 104,300 | +100.0% | 0.19% | – |
| New | AEON BIOPHARMA INCcl a | $1,444,672 | – | 257,977 | +100.0% | 0.17% | – | |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $1,386,483 | – | 30,546 | +100.0% | 0.17% | – |
| New | DISC MEDICINE INCcall | $1,334,232 | – | 284 | +100.0% | 0.16% | – | |
| CBAY | New | CYMABAY THERAPEUTICS INCput | $1,216,656 | – | 816 | +100.0% | 0.15% | – |
| New | VISTAGEN THERAPEUTICS INC | $1,200,485 | – | 229,100 | +100.0% | 0.14% | – | |
| QURE | New | UNIQURE NV | $1,055,919 | – | 157,365 | +100.0% | 0.13% | – |
| LLY | New | ELI LILLY & CO | $659,058 | – | 1,227 | +100.0% | 0.08% | – |
| MORF | New | MORPHIC HLDG INCput | $295,539 | – | 129 | +100.0% | 0.04% | – |
| TGTX | New | TG THERAPEUTICS INC | $272,093 | – | 32,547 | +100.0% | 0.03% | – |
| PTCT | New | PTC THERAPEUTICS INC | $243,418 | – | 10,862 | +100.0% | 0.03% | – |
| New | SYNLOGIC INC | $57,459 | – | 20,448 | +100.0% | 0.01% | – | |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $58,080 | – | 4,000 | +100.0% | 0.01% | – |
| XENE | New | XENON PHARMACEUTICALS INCput | $37,576 | – | 11 | +100.0% | 0.01% | – |
| MORF | New | MORPHIC HLDG INCcall | $32,074 | – | 14 | +100.0% | 0.00% | – |
| New | PHAXIAM THERAPEUTICS S Aspon adr new | $1,558 | – | 301 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.